GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2013

Rockland Acquires Epi-Plus Product Line

  • Rockland Immunochemicals acquired the Epi-Plus® antibody product line from 21st Century Biochemicals. Epi-Plus antibodies are multi-assay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP). The company will market the Epi-Plus product line on its e-commerce website and through its existing global distribution network.

    "The acquisition of the Epi-Plus product line expands Rockland’s Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," commented Jim Fendrick, president and CEO of Rockland Immunochemicals. “The fact that the Epi-Plus brand is co-owned by Novus Biologicals also allows us to expand the Rockland brand globally."

    Research in epigenetics has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy. The global revenue market for epigenetics has been estimated at $2.6 billion in 2012 and is expected to reach $8 billion by 2017, a five-year CAGR of 25%.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »